Research programme: G-protein coupled receptor modulators - Trevena

Drug Profile

Research programme: G-protein coupled receptor modulators - Trevena

Latest Information Update: 01 Apr 2015

Price : $50

At a glance

  • Originator Trevena
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Opioid delta receptor modulators; Opioid kappa receptor modulators; Opioid mu receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Major depressive disorder; Pain; Parkinson's disease
  • No development reported Cachexia; Inflammation

Most Recent Events

  • 08 Mar 2017 Trevena plans to initiate a first-in-human trial for TRV 250 in Migraine in Q2 2017
  • 18 Mar 2015 Preclinical trials in Migraine in USA (PO) prior to March 2015
  • 03 May 2012 Trevena and Merck (through its subsidiary) enter into a research collaboration to identify biased ligand compounds
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top